These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2663145)

  • 1. The promise and limitations of controlled-release oral levodopa administration.
    Cedarbaum JM
    Clin Neuropharmacol; 1989 Jun; 12(3):147-66. PubMed ID: 2663145
    [No Abstract]   [Full Text] [Related]  

  • 2. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
    Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
    Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Clin Neurol Neurosurg; 1989; 91(4):303-9. PubMed ID: 2555090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 5. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sinemet - 25/100.
    Med Lett Drugs Ther; 1980 Jun; 22(12):51. PubMed ID: 7374623
    [No Abstract]   [Full Text] [Related]  

  • 12. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
    Friedman JH; Lannon MC
    Clin Neuropharmacol; 1989 Jun; 12(3):220-3. PubMed ID: 2743346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
    Koller WC
    Neurology; 1992 Jan; 42(1 Suppl 1):4-5; discussion 57-60. PubMed ID: 1549200
    [No Abstract]   [Full Text] [Related]  

  • 17. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL; McKeage K
    CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release Sinemet.
    Goetz CG; Tanner CM; Carroll VS; Shannon KM; Klawans HL
    Neurology; 1987 Sep; 37(9):1567-8. PubMed ID: 3627466
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical design and development of a Sinemet controlled-release formulation.
    Dempski RE; Scholtz EC; Oberholtzer ER; Yeh KC
    Neurology; 1989 Nov; 39(11 Suppl 2):20-4. PubMed ID: 2685648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinemet CR for Parkinson's disease.
    Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.